Compare Occidental Petroleum Corporation (OXY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs BIO-TECHNE Corp — how do they compare? Occidental Petroleum Corporation trades at $60.14 (market cap $60.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Occidental Petroleum Corporation is far larger — about 5.3× BIO-TECHNE Corp's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.86%). Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and BIO-TECHNE Corp for 63 Days on average.
| OXY | TECH | |
|---|---|---|
Market Cap | $60.26B | $11.36B |
Volume | 11,718,920 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $66.24 | $72.61 |
52-Week Low | $38.92 | $43.31 |
Typical Hold Time | 92 Days | 63 Days |
Enterprise Value | $79.02B | $11.39B |
Dividend Yield | 1.86% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $58.21, showing slight daily weakness but maintaining a bullish technical trend with strong fundamental metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.40 significantly exceeding the $1.83 forecast. Valuation remains attractive with a P/E of 17.78 and EV/EBITDA of 5.56, while profitability metrics show robust margins and returns.
OXY presents compelling value with analyst consensus price target of $71.40 representing 23% upside potential. The company's debt reduction progress and strong cash flow generation support dividend sustainability. Key risks include oil price volatility and execution challenges in carbon management initiatives. Wall Street sentiment remains positive with 52% buy ratings among analysts.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
